iShares Biotech ETF (IBB) Surges 24% Year-To-Date Amid Moderna's 587% Gain

Biotech stocks are rising sharply in 2025, with the iShares Biotechnology ETF (IBB) gaining 24% through October 23, following a 28% increase last year. Moderna leads with a 587% year-to-date surge despite an 18% drop after leaked clinical data for its cancer vaccine. Analysts highlight a renewed biotech innovation cycle driven by clinical trial successes, mergers and acquisitions, and advances in genomics, mRNA technology, and artificial intelligence.

FDA approvals support sector growth, with about a dozen novel biologic drugs approved in 2025 from 46 total approvals. Approximately 66 novel drugs remain in the pipeline, including cancer and obesity treatments from Moderna, Merck, and Eli Lilly. Experts say AI is enhancing drug development, enabling new predictive models that improve drug discovery processes.

Though the sector faces risks such as long development times and high failure rates, recent strong performance and improved valuations suggest a healthier outlook. The combination of technology innovation and regulatory approvals may lead to more novel drug products reaching the market. This matters for investors as the biotech sector shows potential for sustained gains driven by technological progress and upcoming FDA approvals.